EZH2 overexpression is associated with poor prognosis in patients with glioma

Yanyang Zhang; Xinguang Yu; Ling Chen; Zhibin Zhang; Shiyu Feng

doi:10.18632/oncotarget.13478

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

EZH2 overexpression is associated with poor prognosis in patients with glioma

Yanyang Zhang, Xinguang Yu, Ling Chen, Zhibin Zhang and Shiyu Feng _

PDF | HTML | How to cite

Oncotarget. 2017; 8:565-573. https://doi.org/10.18632/oncotarget.13478

Metrics: PDF 2798 views | HTML 2817 views | ?

Abstract

Yanyang Zhang1,*, Xinguang Yu1,*, Ling Chen1, Zhibin Zhang1, Shiyu Feng1

1Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

*These authors contributed equally to this work

Correspondence to:

Shiyu Feng, email: [email protected]

Xinguang Yu, email: [email protected]

Keywords: EZH2, glioma, biomarker, prognosis

Received: July 20, 2016 Accepted: November 14, 2016 Published: November 21, 2016

ABSTRACT

Previous studies have investigated the prognostic value of enhancer of zeste homolog 2 (EZH2) expression in patients with glioma but conclude contradictory results. We aimed to comprehensively evaluate the prognostic role of EZH2 in glioma by meta-analysis. The databases of PubMed, Embase and Web of Science were searched. Hazard ratio (HR) and 95% confidence interval (CI) were combined to assess the association between EZH2 and overall survival (OS) as well as progression-free survival (PFS). Odd ratio (OR) and 95% CI were calculated to investigate the relevance of EZH2 on clinical factors. Six studies with 575 patients were included for meta-analysis. The results showed that EZH2 overexpression was correlated with poor OS (n = 6, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001) and PFS (n = 3, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001). Subgroup analysis showed that EZH2 had enhanced prognostic value in Asian patients, for WHO grade I-IV and when using immunohistochemistry (IHC) method. In addition, EZH2 was associated with KPS score < 80. No evidence of publication bias was found in this meta-analysis. In conclusion, the present study showed that EZH2 was a potential prognostic marker for poor OS, PFS and lower KPS score in glioma patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13478

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

EZH2 overexpression is associated with poor prognosis in patients with glioma

Abstract